RNAi: Paving the Way to a New Class of Treatments

(DGIwire) – These are exciting times for gene therapy. As Business Insider recently reported, a biopharmaceutical company announced positive results from a late-stage clinical study of a drug for a rare nerve disorder, familial amyloid polyneuropathy. This drug, notes a report in STAT, harnesses a phenomenon called RNA interference (RNAi). This is a naturally occurring […]

close